[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SIPO Biotechnology Co. Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100559667","phase-1-preliminary-evaluation-of-the-safety-and-tolerability-of-spot-mrna01-subcutaneously-administered-in-healthy-subjects-100559667",false,"NCT06567119","Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.","Inclusion Criteria:\n\nAged 18 to 75 years inclusive at the time of informed consent.\n\nExclusion Criteria:\n\n1. Any transient or chronic skin condition, disorder, or infection within 20 cm of the target areas before treatment that, in the opinion of the investigator, may confound study results.\n2. History of laser treatment or chemical peels or any cosmetic anti-aging treatments to the target areas within six months of the study treatment.\n3. History of surgical procedures to target areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results.\n4. Participant with a history of heavy smoking, alcohol or drug abuse or steroid treatment.\n5. Pregnant or breast-feeding females.\n6. History of anaphylaxis or allergic reactions to any constituent of the study product and\u002For local anesthetics, and\u002For history of severe abnormal drug reaction.\n7. Those who have participated in clinical trials of other investigational drugs within 3 months before the study treatment.\n8. Those who are not suitable for subcutaneous injection and biopsy.\n9. Any condition that the investigator or primary physician believes may not be appropriate for participating the study.",true,"ALL","18 Years","75 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.",[28],"Skin Aging",[30,31,32],"SPOT-mRNA01","COL1A1 mRNA","EVs","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-23","ACTUAL",{"date":39,"type":22},"2027-01-11",{"date":41,"type":22},"2029-02-12",{"name":43,"class":44},"SIPO Biotechnology Co. Ltd.","INDUSTRY",""]